Navigation Links
Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)
Date:7/2/2009

erning the Complete Response Letter and the Companies' expectations regarding any meeting with the FDA to discuss the Complete Response Letter. Acura Pharmaceuticals, Inc. and King Pharmaceuticals, Inc. disclaim any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risk factors include, but are not limited to, whether or when the Companies are able to gain FDA approval of the Acurox(R) Tablets NDA; whether additional clinical studies will be required to support FDA approval of the Acurox(R) Tablets NDA; whether or when the Companies may gain FDA approval of product labeling for the proposed indication or for abuse deterrent features; and the benefits of Acurox(R) and the ability of Acurox(R) to deter abuse in actual practice. Other important factors that may cause actual results to differ materially from the forward-looking statements are discussed in the "Risk Factors" section and other sections of each of the Companies' Annual Reports on Form 10-K for the year ended December 31, 2008 and their respective Quarterly Reports on Form 10-Q for the quarter ended March 31, 2009, each of which is on file with the U.S. Securities and Exchange Commission.


'/>"/>
SOURCE King Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
2. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
3. SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
5. Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System
6. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
7. Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
8. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
9. AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria
10. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
11. Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... and fiscal 2014 ended July 31, 2014 on Monday, September ... to discuss the results at 11:00 AM ET. Participating in ... Andrew A. Krakauer , President and CEO; Jorgen ... A. Sheldon , Senior Vice President, CFO and Treasurer; and ...
(Date:9/22/2014)... , Sept. 22, 2014  Inovio Pharmaceuticals, Inc. ... has initiated a phase I clinical trial in ... the safety, tolerability, and immunogenicity of INO-3106. This ... causes most aerodigestive cancers. Aerodigestive cancers ... cords, and parts of the esophagus and windpipe. ...
(Date:9/22/2014)... , Sept. 22, 2014  Seres Health, a clinical-stage ... the human microbiome, today announced that it has been ... Fierce 15 biotechnology companies, designating it as one of ... "Amid a great deal of ain,t-it-cool ... focus and commitment to practical therapeutic development," says ...
Breaking Medicine Technology:Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4Seres Health Named a "Fierce 15" Biotech Company for 2014 2
... Jan. 4, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: ... company focused on cardiac and vascular surgery, announced today ... the position of Vice President, Research and Development; and ... Vice President, Market Development Surgical Adhesives and Starch Medical ...
... /PRNewswire-Asia/ -- The 2011 Medical Korea Awards ceremony was ... the awards ceremony, 10 outstanding medical tourism service providers ... medical tourism agencies, designated as ,first movers, in the ... Yonsei Severance Hospital (General Director: Park Yong-won) won this ...
Cached Medicine Technology:CryoLife Enhances Management Team with Promotions 2CryoLife Enhances Management Team with Promotions 3CryoLife Enhances Management Team with Promotions 4CryoLife Enhances Management Team with Promotions 5Medical Korea Offers 2011 Awards to Top Medical Tourism Service Providers (Institutions) 2
(Date:9/22/2014)... A novel study by the Cancer Science Institute ... of Singapore (NUS) found that an increase in ... that are directly implicated in acute myelogenous leukaemia ... Led by Associate Professor Chng Wee Joo, Deputy ... and Director of the National University Cancer Institute, ...
(Date:9/22/2014)... Thousand Oaks dentist , Dr. Sharon ... Invisalign is a type of orthodontic treatment that can ... can vary based on the extent of the dental ... needed. During this promotion, Dr. Shamoiel is offering complete ... of the adult population has an unhealthy bite, and ...
(Date:9/22/2014)... HealthDay Reporter FRIDAY, Sept. 19, ... with type 2 diabetes found that intensively lowering blood ... strokes and deaths. But intensive blood sugar control didn,t ... study, investigators followed nearly 8,500 participants of a completed ... and blood sugar levels strictly controlled, while others had ...
(Date:9/22/2014)... Oklahoma (PRWEB) September 22, 2014 ... of thought which advocates addiction as a disease ... disease; one with the addicted person being chronically ... experience long periods of sobriety. , Narconon ... Oklahoma, delivers a non-traditional and holistic approach to ...
(Date:9/22/2014)... The Little Gym of Houston , ... charitable organization based in Nashville, Tennessee that provides shoes to ... A pair of shoes can, seriously, change the entire life ... feet. Confidence, comfort, and health are all improved when a ... to play, grown, and live. Aside from the good feeling ...
Breaking Medicine News(10 mins):Health News:Singapore researchers discover a gene that increases incidence of AML 2Health News:Thousand Oaks Cosmetic Dentist, Sharon Shamoiel DDS, Is Now Offering a Special on Invisalign 2Health News:Tight Blood Sugar Control Doesn't Prevent Strokes in Diabetics: Study 2Health News:Tight Blood Sugar Control Doesn't Prevent Strokes in Diabetics: Study 3Health News:Narconon Arrowhead Offers Information on Disease Theory of Addiction in New Release of Booklet 2Health News:Narconon Arrowhead Offers Information on Disease Theory of Addiction in New Release of Booklet 3Health News:The Little Gym of Houston and Stride Rite Partner to Support Soles4Souls 2
... stock was ... $3.81 per share, IRVINE, Calif., Feb. ... received a letter, dated February 4,2008, from The NASDAQ Stock Market, notifying ... price of the,Company,s common stock had been below the $1.00 minimum bid ...
... standard, invasive method , , TUESDAY, Feb. 5 (HealthDay News) -- ... spread may be better than traditional, invasive procedures. , Although ... Journal of the American Medical Association , needs to ... people with lung cancer or suspected lung cancer. , "Currently, ...
... - A Road Taken Together, NORTH ADAMS, ... groups across the globe will join the National,Patient ... Week,March 2-8. The theme of the week, Patient ... for safer health care through partnership,among providers, patients, ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), ... announced today that it has signed a,definitive agreement ... Home,Health Care Affiliates, Inc. and certain of its ... subject to post-closing adjustments., The transaction will ...
... suggests that a minimally invasive approach may accurately determine ... study in the February 6 issue of JAMA. , ... death in the United States. Determining the stage of ... prognosis, according to background information in the article. ...
... - ... - Special Items Reduce Net Income by $17.9 ... ), a world leader in products and technologies to,treat advanced cardiovascular disease, ... million, or $0.27 per diluted,share, compared to net income of $20.7 million, ...
Cached Medicine News:Health News:IDM Pharma Receives Notification from NASDAQ Relating to Minimum Bid Price 2Health News:Less Invasive Way to Stage Lung Cancer Shows Promise 2Health News:Less Invasive Way to Stage Lung Cancer Shows Promise 3Health News:Patient Safety Awareness Week March 2 to March 8, 2008 2Health News:Gentiva(R) Health Services Agrees to Acquire Major Home Health Provider in CON State of Mississippi 2Health News:Gentiva(R) Health Services Agrees to Acquire Major Home Health Provider in CON State of Mississippi 3Health News:Gentiva(R) Health Services Agrees to Acquire Major Home Health Provider in CON State of Mississippi 4Health News:Less invasive methods may provide accurate means to determine lung cancer stage 2Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 2Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 3Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 4Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 5Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 6Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 7Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 8Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 9Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 10Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 11Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 12Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 13Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 14Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 15Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 16Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 17
... IDT 10 offers premium-level performance with a range ... other systems in the 8- and 10-slice market. ... rotation time, and submillimeter isotropic imaging set it ... a simple upgrade to a 16-slice system make ...
... The TLIF Instruments are designed to ... of non-structural bone graft during interbody fusion. ... to allow easy use during TLIF, for ... can also be used very effectively in ...
... a versatile set of instruments intended ... procedures precise, simple and quick every ... is the ideal complement to Spinal ... Bacfix Thoracolumbar System. This innovative instrument ...
CD HORIZON SEXTANT Rod Insertion System...
Medicine Products: